



Weill Cornell Medicine-Qatar
Continuing Professional Development

Diabetic Foot Challenge

R A Malik

Professor of Medicine,
Weill Cornell Medicine-Qatar
& Weill Cornell Medicine in NY

DISCLOSURE STATEMENT

Speaker:

Rayaz A. Malik, MD

- Has disclosed that he serves on the Speaker's Bureau for Pfizer and Lilly
- Will not be discussing the off-label or investigational use of products




Referral

- 50 year old Qatari male with Type 1 DM 32 years.
- HbA1c 6.8%
- BP: 118/64
- ACR: 1.2, eGFR-86
- Lipids normal (Statin)



What Next?






OCT

RNFL Single Exam Report OU
SPECTRALIS® Tracking Laser Tomography

HEIDELBERG
ENGINEERING

Diagnosis: ---

Comment: ---




Notes:





Date: 12/9/2015

Signature:

Corneal Confocal Microscopy






Corneal Confocal Microscopy



Corneal nerve fibre density (CNFD): 26.0 ± 10.0 no./mm² (control: 36.5 /mm²)
Corneal nerve branch density (CNBD): 83.3 ± 40.3 no./mm² (control: 76.0 /mm²)
Corneal nerve fibre length (CNFL): 21.9 ± 6.6 mm/mm² (control: 25.8 mm/mm²)

Electrophysiology



Nerve	Amplitude (mV)	NCV (m/s)
Median	5.8	20 (45-70)
Ulnar	0.5	19 (48-74)
Radial	0.6	10 (48-70)
Peroneal	1.6	14 (44+)
Sural	2.5	13 (46-64)

Genetics

**But
No Family Hx.
Age 50**




NORMAL



Genetics

MLPA* (Multiplex Ligation-dependent Probe Amplification) (deletion or duplication) of PMP22 gene

**De Novo
Mutation
10%**



**Son 14
Clumsy**

Probes for each of the five PMP22 exons are present in this probemix.

CMT: Incidence 1:2500 (AD)

(1) *PMP22* duplications (CMT1A) (60%) encodes a 22 KD protein in Schwann Cells

(2) *PMP22* deletions (HNPP)

(3) *PMP22* point mutations (both phenotypes.)

ADA 2016: Clinical Pearls

- Most common forms of DN are DSPN and AN.
- DSPN is a length-dependent symmetrical disorder and most commonly predominantly sensory.
- Neuropathy may be present in patients with metabolic syndrome, and/or impaired glucose tolerance.
- **Non-diabetic neuropathies** may occur in diabetes, may be more prevalent than in non-diabetic populations (e.g., higher incidence of B12 deficiency with long-term metformin treatment; CIDP), and should be actively excluded.

Atypical Neuropathy

- Rapid progression ☐
- Asymmetry ☐
- Motor > Sensory ☒
- Other Complications ☐
- Family History ☒
- Drugs ☐

A swollen foot

- 52 yr old male
- T1D for 25yrs
- Retinopathy: PRP
- HTN 5yrs, eGFR 56
- Long term Urinary Catheter
- Swelling foot 2 months

Presentation



A&E: Diagnosis?


- 1. Cellulitis**
- 2. DVT**
- 3. Gout**
- 4. Charcot**
- 5. Osteomyelitis**

Investigations

- ESR 80
- CRP 142
- Pro-calcitonin 4.6 ng/mL


Procalcitonin

- Procalcitonin is a 116 amino-acid peptide - precursor of the hormone calcitonin




Procalcitonin in sepsis

- Bacterial toxins (gram+/gram-) and cytokines stimulate production of Procalcitonin in all parenchymal tissues.
- Non endocrine tissues e.g. liver, lung, brain etc. do not have endocrine granules where calcitonin can be stored
- Therefore PCT is immediately released into the bloodstream



PCT: Sepsis diagnosis



- PCT levels accurately differentiate sepsis from noninfectious inflammation*
- PCT has been demonstrated to be the best marker for differentiating patients with sepsis from those with systemic inflammatory reaction not related to infectious cause

DFU vs Osteomyelitis

DFU vs osteomyelitis

- ESR >67 mm/hr (sensitivity 84%; specificity 75%)
- CRP >14 mg/L (sensitivity 85%; specificity 83%)
- Pro-calcitonin >0.3 ng/mL (sensitivity 81%; specificity 71%)

The value of inflammatory markers to diagnose and monitor diabetic foot osteomyelitis

- Osteo (n=24) v DFU (n=11).
- ESR, CRP, IL-6, IL-8, TNF α , MCP-1, MIP1 α
- **Pro-calcitonin (PCT) (P<0.049).**

Imaging?

Probe to Bone



X-Ray

Bone Scan

CT

MRI

Which test?

TABLE

Diagnosing osteomyelitis: How the tests stack up*

Type of evidence	Number of patients	Diagnostic test	Gold standard comparison	Pooled results
Meta-analysis of 9 cohort trials [†] (8 prospective, 1 retrospective)	Total N=612			
	4 trials; N=177	Plain film	Histopathology or bone culture	Sensitivity 54 % Specificity 68 % LR+=1.7 LR-=0.68
	4 trials; N=135	MRI	Histopathology or bone culture	Sensitivity 90 % Specificity 79 % LR+=4.3 LR-=0.13
	6 trials; N=185	Bone scan	Histopathology or bone culture	Sensitivity 81 % Specificity 28 % LR+=1.1 LR-=0.68
	2 trials; N=288	PTB	Histopathology or bone culture	Sensitivity 60 % Specificity 91 % LR+=6.7 LR-=0.44
Meta-analysis [†] of 21 cohort trials [†] (8 prospective, 13 retrospective)	Total N=1027			
	1 trial; N=35	Ulcer >2 cm ²	Bone biopsy	LR+=7.2 LR-=0.48
	3 trials; N=75	PTB	Bone biopsy	LR+=6.4 LR-=0.39
	4 trials; N=108	ESR >70 mm/hr	Bone biopsy	LR+=11 LR-=0.34
	16 trials; N= 567 (data pooled for 7 trials; N=217)	Plain film	Bone biopsy	LR+=2.3 LR-=0.63

ESR, erythrocyte sedimentation rate; LR+, positive likelihood ratio; LR-, negative likelihood ratio; MRI, magnetic resonance imaging; PTB, probe to bone test.

* Numbers of trials and patients don't add up because multiple diagnostic tests were used in some trials.

† 10 trials were graded as a level II or III (Included a blind comparison to the gold standard) and the rest were of low quality because they lacked blinding.

Diagnosis?

1. Cellulitis
2. DVT
3. Gout
4. Charcot
5. Osteomyelitis

Case 2

- 45yrs old male.
 - Type 1 diabetes 30 yrs.
 - eGFR 38.
 - Swelling right foot >1 month.
-
- CRP 2
 - ESR 5
 - Pro-calcitonin 0.1ng/ml



Is There a Systemic Inflammatory Response in the Acute Charcot Foot?

- 36 consecutive patients who presented to the Diabetic Foot Clinic with a red, hot swollen foot
- Skin foot temperature 3.1°C ($2.4 - 4.2$) $>$ in the Charcot compared with the contralateral foot

HOWEVER


- Median CRP: 5.8 mg/l ($5-11$) and <5 mg/l in 47.2% of patients
- Median ESR: 21 mm/h ($13-36$)
- WCC: 7.0 ($4-11$).

Offloading treatment is linked to activation of proinflammatory cytokines and start of bone repair and remodeling in Charcot arthropathy patients



Folestad et al. Foot & Ankle Research 2015; 8: 72-84

Imaging



Diagnosis

1. Cellulitis

2. DVT

3. Gout

4. Charcot

5. Osteomyelitis

Charcot: Pathogenesis



Neurovascular


Charcot 1868

Neurotraumatic

Volkman 1870



Pro-inflammatory cytokines (IL-1 β , TNF- α)
Activation (RANKL- NF κ B)
OSTEOCLASTS (CGRP/VIP)



Wnt/ β -catenin pathway, sclerostin and dickkopf-1.
OSTEOBLASTS (SP/CGRP)


Charcot: Imaging



MRI: Sen-76.9%,
Spec- 75%
T1 increased
T2 decreased



F¹⁸ FDG PET:
Sen-100%, Spec-93%



Management?

Off-loading

Bisphosphonates

Calcitonin

5 yr malignancy: 4.1 v 2.9%



Denosumab

RANK-L inhibitor (Osteoclasts)

Teriparatide

Recombinant PTH (Osteoblasts)

Surgery

Exostectomy, Arthrodesis

Thank you